Sella, Tal
Exman, Pedro
Ren, Siyang
Freret, Taylor S.
Economy, Katherine E.
Chen, Wendy Y.
Parsons, Heather A.
Lin, Nancy U.
Moy, Beverly
Tung, Nadine M.
Partridge, Ann H.
Tayob, Nabihah
Mayer, Erica L. http://orcid.org/0000-0001-5430-8957
Funding for this research was provided by:
Goldfarb Advanced Fellowship in Breast Oncology at Dana-Farber Cancer Institute
American Physicians Fellowship for Medicine in Israel
Pinchas Borenstein Talpiot Medical Leadership Program, Chaim Sheba Medical Center, Tel-Hashomer, Israel
Article History
Received: 27 December 2021
Accepted: 30 April 2022
First Online: 17 June 2022
Declarations
:
: Heather A. Parsons has received funding to the institution from Puma. Nancy U. Lin has received grant/contract funding to the institution from Genentech, Merck, Pfizer, Seattle Genetics, Zion Pharmaceuticals, Olema Pharmaceuticals, and AstraZeneca; consulting fees/honorarium for consulting/ad board participation from Puma, Seattle Genetics, AstraZeneca, Daiichi-Sankyo, Denali Therapeutics, Olema Pharma, Prelude Therapeutics, Aleta BioPharma, Voyager Therapeutics, Affinia Therapeutics, and Pfizer; royalties from UpToDate; and stock and other ownership interests in Artera Inc. Nadine M. Tung has received research funding from AstraZeneca. Erica L. Mayer has received consulting/advising fees from Novartis, Lilly, Gilead, and AstraZeneca. All remaining authors declared that they have no conflict of interest.